risperidone has been researched along with Dyslipidemia in 13 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Risperidone use in children and adolescents is associated with the development of metabolic disorders including increased accumulation of body fat, dyslipidemia, and glucose and insulin metabolism dysregulation." | 7.96 | Exercise intervention for preventing risperidone-induced dyslipidemia and gluco-metabolic disorders in female juvenile rats. ( Deng, C; Han, M; Sylvester, E; Yi, W, 2020) |
| "Risperidone use in children and adolescents is associated with the development of metabolic disorders including increased accumulation of body fat, dyslipidemia, and glucose and insulin metabolism dysregulation." | 3.96 | Exercise intervention for preventing risperidone-induced dyslipidemia and gluco-metabolic disorders in female juvenile rats. ( Deng, C; Han, M; Sylvester, E; Yi, W, 2020) |
| "Children treated with risperidone or quetiapine are at a significant risk for developing obesity, elevated waist circumference, and dyslipidemia during 12 months of treatment." | 3.81 | Increased Risk of Obesity and Metabolic Dysregulation Following 12 Months of Second-Generation Antipsychotic Treatment in Children: A Prospective Cohort Study. ( Davidson, J; Nguyen, D; Panagiotopoulos, C; Ronsley, R, 2015) |
| "RLAI and OP show good short- and long-term safety when treating patients with schizophrenia, with uncommon discontinuation due to adverse effects." | 2.46 | Long-acting atypical injectable antipsychotics in the treatment of schizophrenia: safety and tolerability review. ( Cañas, F; Möller, HJ, 2010) |
| "Data for 60,162 subjects with type 1 diabetes up to the age of 25 years registered in the nationwide German/Austrian Diabetes Survey were included in the analysis." | 1.42 | Comparison of glycemic and metabolic control in youth with type 1 diabetes with and without antipsychotic medication: analysis from the nationwide German/Austrian Diabetes Survey (DPV). ( Bartus, B; Bollow, E; Galler, A; Haberland, H; Holl, RW; Meusers, M; Näke, A; Schober, E, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (46.15) | 29.6817 |
| 2010's | 6 (46.15) | 24.3611 |
| 2020's | 1 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Sylvester, E | 1 |
| Yi, W | 1 |
| Han, M | 1 |
| Deng, C | 1 |
| Pisano, S | 1 |
| Gritti, A | 1 |
| Catone, G | 1 |
| Pascotto, A | 1 |
| Galler, A | 1 |
| Bollow, E | 1 |
| Meusers, M | 1 |
| Bartus, B | 1 |
| Näke, A | 1 |
| Haberland, H | 1 |
| Schober, E | 1 |
| Holl, RW | 1 |
| Bonaccorso, S | 1 |
| Sodhi, M | 1 |
| Li, J | 1 |
| Bobo, WV | 1 |
| Chen, Y | 1 |
| Tumuklu, M | 1 |
| Theleritis, C | 1 |
| Jayathilake, K | 1 |
| Meltzer, HY | 1 |
| Ronsley, R | 1 |
| Nguyen, D | 1 |
| Davidson, J | 1 |
| Panagiotopoulos, C | 1 |
| Lee, E | 1 |
| Leung, CM | 1 |
| Duncan, EJ | 1 |
| Woolson, SL | 1 |
| Hamer, RM | 1 |
| Dunlop, BW | 1 |
| Cañas, F | 1 |
| Möller, HJ | 1 |
| Adeneye, AA | 1 |
| Agbaje, EO | 1 |
| Olagunju, JA | 1 |
| Lin, SK | 1 |
| Chen, CK | 1 |
| Wooten, J | 1 |
| Perlis, RH | 1 |
| Perez-Iglesias, R | 1 |
| Crespo-Facorro, B | 1 |
| Amado, JA | 1 |
| Garcia-Unzueta, MT | 1 |
| Ramirez-Bonilla, ML | 1 |
| Gonzalez-Blanch, C | 1 |
| Martinez-Garcia, O | 1 |
| Vazquez-Barquero, JL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Monitoring of Metabolic Adverse Events of Second Generation Antipsychotics in a Naive Pediatric Population Followed in Mental Health Outpatient and Inpatient Clinical Settings (MEMAS Prospective Study)[NCT04395326] | 120 participants (Anticipated) | Observational | 2017-01-01 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for risperidone and Dyslipidemia
| Article | Year |
|---|---|
Long-acting atypical injectable antipsychotics in the treatment of schizophrenia: safety and tolerability review.
Topics: Administration, Oral; Antipsychotic Agents; Benzodiazepines; Delayed-Action Preparations; Dyslipidem | 2010 |
Metabolic effects of the atypical antipsychotics.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Diabetes Mellitus; Dibenzothiazepine | 2007 |
Treatment of bipolar disorder: the evolving role of atypical antipsychotics.
Topics: Antipsychotic Agents; Aripiprazole; Arrhythmias, Cardiac; Benzodiazepines; Bipolar Disorder; Diabete | 2007 |
2 trials available for risperidone and Dyslipidemia
| Article | Year |
|---|---|
The brain-derived neurotrophic factor (BDNF) Val66Met polymorphism is associated with increased body mass index and insulin resistance measures in bipolar disorder and schizophrenia.
Topics: Adult; Alleles; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Blood Glucose; Body Mass In | 2015 |
A 12-week randomized clinical trial to evaluate metabolic changes in drug-naive, first-episode psychosis patients treated with haloperidol, olanzapine, or risperidone.
Topics: Adolescent; Adult; Anthropometry; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass In | 2007 |
8 other studies available for risperidone and Dyslipidemia
| Article | Year |
|---|---|
Exercise intervention for preventing risperidone-induced dyslipidemia and gluco-metabolic disorders in female juvenile rats.
Topics: Animals; Antipsychotic Agents; Blood Glucose; Body Mass Index; Dyslipidemias; Female; Glucose Tolera | 2020 |
Antipsychotic-induced dyslipidemia treated with omega 3 fatty acid supplement in an 11-year-old psychotic child: a 1-year follow-up.
Topics: Antipsychotic Agents; Child; Dietary Supplements; Dyslipidemias; Fatty Acids, Omega-3; Follow-Up Stu | 2013 |
Comparison of glycemic and metabolic control in youth with type 1 diabetes with and without antipsychotic medication: analysis from the nationwide German/Austrian Diabetes Survey (DPV).
Topics: Adolescent; Adult; Albuminuria; Antipsychotic Agents; Blood Glucose; Body Mass Index; Diabetes Compl | 2015 |
Increased Risk of Obesity and Metabolic Dysregulation Following 12 Months of Second-Generation Antipsychotic Treatment in Children: A Prospective Cohort Study.
Topics: Adolescent; Antipsychotic Agents; Anxiety Disorders; Attention Deficit and Disruptive Behavior Disor | 2015 |
Atypical antipsychotics and metabolic outcomes in Chinese patients: a comparison of olanzapine and risperidone.
Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; China; Cross-Sectional Studies; Dose-Response Re | 2008 |
Risk of lipid abnormality with haloperidol, olanzapine, quetiapine, and risperidone in a Veterans Affairs population.
Topics: Antipsychotic Agents; Benzodiazepines; Case-Control Studies; Dibenzothiazepines; Dyslipidemias; Fema | 2009 |
Metformin: an effective attenuator of risperidone-induced insulin resistance hyperglycemia and dyslipidemia in rats.
Topics: Animals; Antipsychotic Agents; Blood Glucose; Disease Models, Animal; Dyslipidemias; Glyburide; Huma | 2011 |
Reversal of antipsychotic-induced hyperprolactinemia, weight gain, and dyslipidemia by aripiprazole: A case report.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Dyslipidemias; Female; Humans; Hyperprolactinemia; Obesit | 2006 |